Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
JNCI: Journal of the National Cancer Institute · 01.05.2025 · 117 (5) · 889-897
DOI: 10.1093/jnci/djae314 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 05.12.2024. Verfasst von Yara Abdou und 23 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Racial Groups, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Hope Foundation for Cancer Research, AstraZeneca.
Abstract (Originalsprache)
Background
The phase III RxPONDER trial has affected treatment for node-positive (1-3), hormone receptor-positive, HER2-negative breast cancer with a 21-gene recurrence score (RS) less than 26. We investigated how these findings apply to different racial and ethnic groups within the trial.
Methods
The trial randomly assigned women to endocrine therapy (ET) or to chemotherapy plus ET. The primary clinical outcome was invasive disease-free survival (IDFS), with distant relapse-free survival (DRFS) as a secondary outcome. Multivariable Cox models were used to evaluate the association between race/ethnicity and survival outcomes, adjusting for clinicopathological characteristics, RS, and treatment.
Results
A total of 4048 women with self-reported race/ethnicity were included: Hispanic (15.1%), non-Hispanic Black (NHB) (6.1%), Native American/Pacific Islander (0.8%), Asian (8.0%), and non-Hispanic White (NHW) (70%). No differences in RS distribution, tumor size, or number of positive nodes were observed by race/ethnicity. Relative to NHWs, IDFS was worse for NHB participants (5-year IDFS 91.6% vs 87.1%, HR = 1.37; 95% CI = 1.03 to 1.81) and better for Asians (91.6% vs 93.9%, HR = 0.64; 95% CI = 0.46 to 0.91). Relative to NHW, DRFS was worse for NHB participants (5-year DRFS 95.8% vs 91.0%, HR = 1.65; 95% CI = 1.17 to 2.32) and better for Asians (95.8% vs 96.7%, HR = 0.59; 95% CI = 0.37 to 0.95). Adjusting for clinical characteristics, particularly body mass index, diminished the effect of race on outcomes. Chemotherapy treatment efficacy did not differ by race/ethnicity.
Conclusions
NHB women had worse clinical outcomes compared with NHWs in the RxPONDER trial despite similar RS and comparable treatment. Our study emphasizes the persistent racial disparities in breast cancer outcomes while highlighting complex interactions among contributing factors. Trial Registration ClinicalTrials.gov: NCT01272037.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
- SWOG Statistics and Data Management Center, Seattle, WA, United States.
- American Society of Clinical Oncology, Alexandria, VA, United States.
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- Loyola University Medical Center, Maywood, IL, United States.
- University of Michigan, Ann Arbor, MI, United States.
ORCID-Profile: Yara Abdou, William E Barlow, Funda Meric-Bernstam, Daniel F Hayes, Nancy U Lin, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Anne F Schott, Priyanka Sharma, Jieling Miao, Joseph M Unger, Gabriel N Hortobagyi, Lajos Pusztai
Förderung
- NCI NIH HHS
- Hope Foundation for Cancer Research
- AstraZeneca
- Susan G. Komen for the Cure Research Program
- NIH HHS
- Genomic Health
- Breast Cancer Research Foundation
- AbbVie
Zitieren
APA
Abdou, Y., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., Lin, N. U., Perez, E. A., Goldstein, L. J., Chia, S. K. L., Dhesy-Thind, S., Rastogi, P., Alba, E., Delaloge, S., Schott, A. F., Shak, S., Sharma, P., Lew, D. L., Miao, J., …, & Kalinsky, K. (2025). Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. JNCI: Journal of the National Cancer Institute, 117(5), 889-897. https://doi.org/10.1093/jnci/djae314
Vancouver
Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. JNCI: Journal of the National Cancer Institute. 2025;117(5):889-897. doi:10.1093/jnci/djae314
BibTeX
@article{Abdou2025,
author = {Abdou, Yara and Barlow, William E and Gralow, Julie R and Meric-Bernstam, Funda and Albain, Kathy S and Hayes, Daniel F and Lin, Nancy U and Perez, Edith A and Goldstein, Lori J and Chia, Stephen K L and Dhesy-Thind, Sukhbinder and Rastogi, Priya and Alba, Emilio and Delaloge, Suzette and Schott, Anne F and Shak, Steven and Sharma, Priyanka and Lew, Danika L and Miao, Jieling and Unger, Joseph M and Tripathy, Debasish and Hortobagyi, Gabriel N and Pusztai, Lajos and Kalinsky, Kevin},
title = {Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
volume = {117},
number = {5},
pages = {889--897},
doi = {10.1093/jnci/djae314}
}
EUVIMED